1. Home
  2. GOAI vs CGTX Comparison

GOAI vs CGTX Comparison

Compare GOAI & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eva Live Inc. Common Stock

GOAI

Eva Live Inc. Common Stock

N/A

Current Price

$2.64

Market Cap

93.9M

Sector

Technology

ML Signal

N/A

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.17

Market Cap

102.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOAI
CGTX
Founded
2015
2007
Country
United States
United States
Employees
3
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.9M
102.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GOAI
CGTX
Price
$2.64
$1.17
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
116.1K
2.1M
Earning Date
04-10-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$18.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.07
$0.43
52 Week High
$6.67
$3.83

Technical Indicators

Market Signals
Indicator
GOAI
CGTX
Relative Strength Index (RSI) 42.14 47.16
Support Level $2.07 $1.07
Resistance Level $4.36 $1.23
Average True Range (ATR) 0.36 0.18
MACD 0.03 -0.03
Stochastic Oscillator 23.15 28.92

Price Performance

Historical Comparison
GOAI
CGTX

About GOAI Eva Live Inc. Common Stock

Eva Live Inc is a United States-based technology company that has developed an automated and intelligent advertiser campaign management platform, Eva Platform, which enables advertisers ('customers, clients') to buy advertising space on several digital channels to reach their desired audience. The company also works with Businesses that utilize its in-house digital marketing capabilities, including advice, creative services, account management, production of advertising materials, media planning, and buying.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: